Objective: There is controversery data about the use of drug-eluting stents versus bare-metal stents in saphenous vein graft lesions. Our purpose was to compare the outcomes of patients receiving drug-eluting stents or bare-metal stents in saphenous vein graft percutaneous coronary interventions.

Material and Method: All patients undergoing saphenous vein graft percutaneous coronary intervention with a drug-eluting stent or bare-metal stent alone from January 2013 to December 2017 at our center were assessed retrospectively. Major adverse cardiac events including myocardial infarction, target vessel revascularization and death were recorded at follow up period.

Results: Ninety two patients included the study. Of these,72 patiens received a drug eluting stent and 20 patients had a bare metal stent. The median follow-up was 29 (range 0-66) months. There were no different outcomes for myocardial infarction, death and target vessel revascularization between drug eluting stent and bare metal stent. The rate of major adverse cardiac event -free survival was %71.3 in the drug eluting stent group and %71.8 in the bare metal stent group (p =0.660).

Conclusion: There was no significant difference in long-term outcomes between drug eluting stent and bare metal stent in saphenous vein graft percutaneous coronary interventions in our real world experience. However, more cases and long-term follow-up are warranted.